Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Joshua Fitch, Senior Editor
Advertisement
Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown State University in Youngstown, Ohio in 2020 with a degree in telecommunications and journalism. He started his career as a news and sports videographer before becoming an on-air sports anchor at the NBC-affiliated news station in Youngstown. Fitch briefly worked as a national content writer for a Chicago-based national television station before joining the Contemporary Pediatrics team. He can be reached at: jfitch@mjhlifesciences.com.
Articles by Joshua Fitch, Senior Editor
Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body psoriasis.
The once-daily, steroid-free topical is now approved to treat plaque psoriasis of the scalp and body in patients aged 12 years and older.
The expanded indication follows original approval in August 2018 for use in previously-treated patients 12 years and older.
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Albuterol-budesonide (Airsupra; AstraZeneca) resulted in a 47% reduction in severe exacerbations in mild asthma vs albuterol alone.
NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes.
Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.
Delandistrogene moxeparvovec-rokl (ELEVIDYS) showed significant motor function improvements in 8- to 9-year-old Duchenne muscular dystrophy patients in part 2 of the phase 3 EMBARK study.
Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.
The nearly 4000 cases in 2023 were the highest number reported in over 30 years, the Task Force stated.
The federal agency provided BioCryst Pharmaceuticals a target action date of September 12, 2025 for potential approval of berotralstat (ORLADEYO).
The administration has set a goal date of October 31 to complete a safety review, public comment period, and to take "appropriate action" in efforts to remove products from the market.
According to the agency, it is seeking public input to "determine whether existing nutrient requirements should be revised based on latest scientific data."
This FDA decision will help to improve clarity and diagnostic accuracy of echocardiograms in pediatric patients, according to GE HealthCare.
Maternal avocado consumption during pregnancy was linked to significantly lower odds of infant food allergy at 12 months.
The in vivo hematopoietic stem cell-directed therapy received rare pediatric disease and orphan drug designations earlier this year.
"Early identification of high-risk neonates may enable targeted strategies to support respiratory health," stated the study investigators.
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.
NEC is a life-threatening condition marked by the death of intestinal tissue, which impacts preterm infants.
Prescriptions for the epinephrine nasal spray are now available for patients aged 4 years and up who weigh 33 to < 66 lbs.
Watch some of our top clips from a number of discussions with experts who presented at PAS 2025.
In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.
Stealth BioTherapeutics' CEO stated, "We hope to gain more information on the revised action date in the coming days."
The human FcRn-blocking monoclonal antibody is indicated for gMG patients aged 12 years and older.
The decision makes pz-cel the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.
In addition, data presented at PAS revealed a predictable pharmacokinetic profile in the newborn population, consistent with adult humans.
One step will be a partnership with the National Institutes of Health to research how food additives impact children's health.
From the FDA approvals of dupilumab and maralixibat tablets to a new puzzler case study, get caught up with our weekly review article.
Advertisement
Advertisement
Advertisement